Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.35 |
| ▸ | GABRD | O14764 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRE | P78334 | 2/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24699587 | 1.00 | OPRM1 (0.50) | OPRM1TSHRTP53ALDH1A1GABRP | |
| SCHEMBL20610005 | 0.84 | TSHR (0.59) | OPRM1TSHRMETAP1ACE2TDP1 | |
| SCHEMBL11284239 | 0.83 | OPRM1 (0.67) | OPRM1TSHRTP53ALDH1A1GABRP | |
| SCHEMBL24026302 | 0.83 | TSHR (0.42) | OPRM1TSHRTP53ALDH1A1METAP1 | |
| SCHEMBL20921481 | 0.83 | OPRM1 (0.59) | OPRM1TSHRTP53ALDH1A1GABRP | |
| SCHEMBL23654175 | 0.83 | OPRM1 (0.59) | OPRM1TSHRTP53ALDH1A1GABRP | |
| SCHEMBL23776132 | 0.83 | OPRM1 (0.59) | OPRM1TP53ALDH1A1ACE2TDP1 | |
| SCHEMBL11125748 | 0.83 | OPRM1 (0.59) | OPRM1TSHRTP53ALDH1A1GABRP | |
| SCHEMBL566853 | 0.81 | — | — | |
| SCHEMBL7887 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014037313-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| US-20090011946-A1 | Use of Sequence Specific Polymers in Chemical Detection | KALINEX (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1839059-A1 | USE OF SEQUENCE SPECIFIC POLYMERS IN CHEMICAL DETECTION | Kalinex (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006069263-A1 | USE OF SEQUENCE SPECIFIC POLYMERS IN CHEMICAL DETECTION | KALINEX (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20050003558-A1 | Biological sample component purification and differential display | CHIRON CORPORATION (US) | 2005-01-06 | — | — | US | disclosed |
| US-6783929-B1 | COMPRISES POLYAMIDE LIGANDS FOR ENHANCED EFFICIENCY OF PROTEOMICS | CHIRON CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6646093-B2 | Extruding auxiliary for cement materials, a mortar thickening agent, an underwater concrete thickening agent, a ceramics forming binder and a moisturizer for hair cosmetics; water and shape retention. | MITSUI CHEMICALS, INC. (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-0789577-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020045724-A1 | Water-souluble polyurthane having comb-shaped hydrophobic group and application thereof | MITSUI TAKEDA CHEMICALS, INC. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1155327-A1 | BIOLOGICAL SAMPLE COMPONENT PURIFICATION AND DIFFERENTIAL DISPLAY | CHIRON CORPORATION (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2001033230-A2 | BIOLOGICAL SAMPLE COMPONENT PURIFICATION AND DIFFERENTIAL DISPLAY | CHIRON CORPORATION (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-0846679-B1 | Process for preparing 1,3-disubstituted urea | SUMIKA FINE CHEMICALS CO LTD (JP) | 2000-09-06 | — | — | EP | disclosed |
| US-5902899-A | Process for preparing 1, 3-disubstituted urea | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 1999-05-11 | — | — | US | disclosed |
| US-5877278-A | SOLID PHASE SYNTHESIS USING TWO SUBMONOMERS-AN ACYLATING AGENT, E.G. A HALOACETIC ACID, AND A PRIMARY AMINE; CYCLIZATION TO PRODUCE MIMETICS OF DRUGS; ELIMINATION OF THE NECESSITY OF PROTECTION GROUPS | CHIRON CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0846679-A2 | Process for preparing 1,3-disubstituted urea | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 1998-06-10 | — | — | EP | disclosed |
| US-5536853-A | Opiate receptor ligands | CHIRON CORPORATION (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0010256-B1 | PROCESS FOR PREPARING SYMMETRIC 1,3-DISUBSTITUTED UREAS | BASF Aktiengesellschaft (DE) | 1982-12-29 | — | — | EP | disclosed |
| EP-0010256-A2 | Process for preparing symmetric 1,3-disubstituted ureas | BASF Aktiengesellschaft (DE) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045724-A1 | Water-souluble polyurthane having comb-shaped hydrophobic group and application thereof | BMI1, ASH2L, HAT1 | OPRM1 2970/4885TSHR 4441/4885TP53 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.